Adaptimmune Therapeutics PLC last reported quarterly results on Aug 13, 2025, for Q2 FY2025 (the quarter ended Jun 30, 2025): revenue of $13.7 million (-89.3% year over year) and diluted EPS of -$0.02. It usually reports 43–44 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 43–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 13, 2025
44 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
14
-89.3%
|
-30
-143.6%
|
-0.02
-150.0%
|
|
May 13, 2025
43 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
7
+28.3%
|
-48
+1.9%
|
-0.03
+0.0%
|
|
Nov 13, 2024
44 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
41
+458.8%
|
-18
+61.4%
|
-0.01
+66.7%
|
|
Aug 12, 2024
43 days after quarter end
|
Q2 FY2024
ended Jun 30, 2024
|
128
+2399.6%
|
70
+425.0%
|
0.04
+300.0%
|
|
May 15, 2024
45 days after quarter end
|
Q1 FY2024
ended Mar 31, 2024
|
6
-88.1%
|
-49
-4781.8%
|
-0.03
|
|
Mar 6, 2024
66 days after quarter end
|
Q4 FY2023
ended Dec 31, 2023
|
0
-97.9%
|
-48
-63.8%
|
-0.04
-18.4%
|
|
Nov 8, 2023
39 days after quarter end
|
Q3 FY2023
ended Sep 30, 2023
|
7
+4.5%
|
-46
-10.1%
|
-0.03
+25.0%
|
|
Aug 9, 2023
40 days after quarter end
|
—
ended Jun 30, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ADAPY (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Abingdon, Oxfordshire
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1621227
- Former names
- Adaptimmune Ltd (until Mar 17, 2015)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.